Wilmington, DE, United States of America

Nikoo Falahatpisheh

This inventor holds 30 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 17 EPO patents, primarily in PI3K Inhibitors. Top assignees: Incyte Corporation, Incyte Holdings Corporation. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nikoo Falahatpisheh. Retrieved from https://idiyas.com/inventor/nikoo-falahatpisheh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 9)

% Patents Active = 96.7

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 17 (Patent Applications = 21)

Average Co-Inventor Count = 5.9

ph-index = 9

Forward Citations = 335(Granted Patents)

Company Filing History:

Incyte Holdings Corporation

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

PI3K Inhibitors

Tertiary Alcohols

Aminopyrazine Derivatives

Heterocyclic Compounds

Spirocyclic Lactams

Janus Kinase Inhibitors

Imidazo Compounds

Pyridine Derivatives

Pyrazole Compounds

BET Protein Inhibitors

Diol Compounds

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12516065 - Tertiary alcohols as PI3K-γ inhibitors (2026-01-06),

2. 12421197 - Aminopyrazine derivatives as PI3K-γ inhibitors (2025-09-23),

3. 12365668 - Aminopyrazine diol compounds as PI3K-y inhibitors (2025-07-22),

4. 12227502 - 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins (2025-02-18),

5. 12030885 - Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors (2024-07-09),

6. 12006320 - Heterocyclic derivatives as PI3K inhibitors (2024-06-11),

7. 11958861 - Spirocyclic lactams as JAK2 V617F inhibitors (2024-04-16),

8. 11952367 - Pyridine and pyridimine compounds as PI3K-gamma inhibitors (2024-04-09),

9. 11926630 - Tertiary alcohols as PI3K-γ inhibitors (2024-03-12),

10. 11926616 - Aminopyrazine diol compounds as PI3K-γ inhibitors (2024-03-12),

11. 11773102 - Heterocyclic compounds as PI3K-γ inhibitors (2023-10-03),

12. 11702416 - 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins (2023-07-18),

13. 11352340 - Pyridine and pyridimine compounds as PI3K-gamma inhibitors (2022-06-07),

14. 11306079 - 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors (2022-04-19),

15. 11225486 - Tertiary alcohols as PI3K-γ inhibitors (2022-01-18),

Title: Innovator Spotlight: Nikoo Falahatpisheh

Introduction

Nikoo Falahatpisheh, based in Wilmington, DE, is a distinguished inventor with an impressive portfolio of 27 patents. His work primarily focuses on developing innovative compounds that serve as potential inhibitors for various proteins, contributing significantly to advancements in medical treatments, particularly in oncology.

Latest Patents

Among his latest patents, two noteworthy inventions include:

1. **1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins** - This invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones that act as inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, offering potential treatment options for conditions like cancer.

2. **Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors** - This application discusses compounds of Formula (I), which present new avenues for targeting PI3K-gamma, furthering research in cancer therapeutics.

Career Highlights

Nikoo has made substantial contributions to the field through his roles at prestigious companies. Notably, he has worked with Incyte Corporation and Incyte Holdings Corporation, where he focused on developing pioneering pharmaceutical solutions aimed at fighting cancer.

Collaborations

Throughout his career, Nikoo has collaborated with various professionals, including notable coworkers like Stacey Shepard and Lixin Shao. These collaborations have played an essential role in enhancing his research and broadening the scope of his inventions.

Conclusion

Nikoo Falahatpisheh’s contributions to the realm of innovation and invention are invaluable, particularly in the fight against cancer. His extensive patent portfolio underscores his commitment to advancing medical science, making him a notable figure in the field of pharmaceutical research.

Profile summary based on public USPTO records.